Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiotensin II antagonists

H R Brunner1, J Nussberger, M Burnier

  • 1Division of Hypertension, University Hospital, CHUV, Lausanne, Switzerland.

Clinical and Experimental Hypertension (New York, N.Y. : 1993)
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triple-combination therapy in the treatment of hypertension: a review of the evidence.

Journal of human hypertension·2017
Same author

Archives of gynecology and obstetrics·2016
Same author

PP125. High mobility group box 1 protein (HMGB1): A pathogenic role in preeclampsia?

Pregnancy hypertension·2015
Same author

Physiological response to whole-body vibration in athletes and sedentary subjects.

Physiological research·2014
Same author

High mobility group box 1 protein (HMGB-1): a pathogenic role in preeclampsia?

Placenta·2014
Same author

[Hypertension. Effects of antihypertensive therapy on cognitive functions].

Revue medicale suisse·2013
Same journal

Adiponectin improves the aortic dissection by inhibiting inflammatory cell infiltration and macrophage pyroptosis.

Clinical and experimental hypertension (New York, N.Y. : 1993)·2026
Same journal

Electroacupuncture for essential hypertension: Mechanistic insights, current clinical evidence, and translational challenges.

Clinical and experimental hypertension (New York, N.Y. : 1993)·2026
Same journal

Association of intracranial atherosclerotic stenosis with 1-year cognitive impairment after acute ischemic stroke or transient ischemic attack: a nationwide prospective cohort study.

Clinical and experimental hypertension (New York, N.Y. : 1993)·2026
Same journal

Frailty as a mediator of the association between hyperuricemia and stroke risk: A prospective cohort study.

Clinical and experimental hypertension (New York, N.Y. : 1993)·2026
Same journal

Synergistic impact of nondipper heart rate and blood pressure on left ventricular hypertrophy in essential hypertension.

Clinical and experimental hypertension (New York, N.Y. : 1993)·2026
Same journal

From clinic to home monitoring: Diagnostic strategies and evidence landscape of white-coat uncontrolled hypertension.

Clinical and experimental hypertension (New York, N.Y. : 1993)·2026
See all related articles

Losartan, an oral angiotensin II receptor blocker, effectively lowers blood pressure in hypertensive patients. Its efficacy appears comparable to ACE inhibitors, warranting further investigation for long-term use.

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Research
  • Renin-Angiotensin System Therapeutics

Background:

  • Parenteral angiotensin II antagonists like saralasin acutely lower blood pressure in essential hypertension.
  • Chronic blockade of angiotensin II at the receptor is now achievable with oral non-peptide inhibitors.
  • Losartan represents a novel approach to antagonizing the renin-angiotensin system.

Purpose of the Study:

  • To evaluate the efficacy and characteristics of the oral angiotensin II receptor inhibitor, losartan.
  • To assess the dose-dependent effects of losartan on the pressor response to angiotensin II.
  • To compare the blood pressure-lowering potential of losartan with existing treatments like ACE inhibitors.

Main Methods:

  • Administration of losartan orally to assess its effects.

Related Experiment Videos

  • Measurement of the pressor response to exogenous angiotensin II.
  • Correlation of losartan's effects with circulating levels of its active metabolite, E3174.
  • Preliminary clinical studies in hypertensive patients.

    • Main Results:

    • Losartan demonstrated dose-dependent inhibition of the pressor response to angiotensin II.
    • The observed effects were closely related to the levels of the active metabolite E3174.
    • Preliminary data suggest losartan's blood pressure-lowering action is equivalent to ACE inhibitors in hypertensive patients.

    Conclusions:

    • Oral losartan effectively antagonizes angiotensin II at the receptor.
    • Losartan shows promise as an antihypertensive agent comparable to ACE inhibitors.
    • Further investigation is required to confirm losartan's long-term efficacy and comparative benefits.